the glocalized network in theragenomic and personalized medicine and the genetics of individual patients safety of drugs
December 26, 2024 – Breast cancer is the second most common cancer in women, with 297,790 estimated new cases in the United States in 2023. The relatively high 5-year overall survival of 90.8% indicates that the disease is curable. The …
Decode cause of aggressive breast cancer in Women of Color Read more »
December 15 2024 – Eighty-seven years after launching the National Cancer Act in the United Stated with the intention of a national combat against cancer, and despite despite significant progress, cancer treatment often falls short, with 50% to 80% of …
Predictive Score: Genetics behind anti-cancer drug resistance Read more »
August 13, 2022 – Breast cancer: Is BIA-ALCL increasing in women in the US? Over the last couple of years, the recognition of an seemingly increased rate of incidence of Anaplastic Large-Cell Lymphoma (ALCL) in woman who received breast implants …
Breast cancer: Is BIA-ALCL increasing in women in the US? Read more »
May 30, 2019 – The American Food and Drug Administration (FDA) recently approved Alpelisib (Piqray) to be used in combination with the FDA-approved endocrine therapy fulvestrant, to treat postmenopausal women, and men, with hormone receptor (HR)-positive, human epidermal growth factor receptor …
The PI3K inhibitor Alpelisib (Piqray) for progressing breast cancer in women (and men) Read more »
May 15, 2018 –An increasing number of women who are diagnosed with breast cancer are opting for multigene sequencing instead of the more limited testing for only BRCA1/ BRCA2 mutations, according to a new report. The findings come from the ICanCAre study, published …
Breast cancer: Multigene sequencing replaces BRCA tests Read more »
February 17, 2018 – In a new study, published in JAMA Oncology online on February 15, 2018, a comparison of the performance of 6 prognostic signatures for estrogen receptor (ER) –positive breast cancer was performed in a secondary analysis of a randomized …
Breast Cancer: Performance of prognostic signatures Read more »
January 13, 2018 – The American Food and Drug Administration (FDA) has just approved the first treatment for breast cancer with a certain inherited genetic mutation. At first glance, this announcement may be just one in the series of announcements by the …
Olaparib Tablets (Lynparza): For breast cancer with BRCA gene mutation Read more »
July 27, 2017 – Jewish women of Ashkenazi descent may be at risk for additional genetic mutations that increase their risk of breast cancer, according to a new study just published in JAMA Oncology. Researchers from University of Washington in Seattle …
Ashkenazi Jewish Women: Little-known Gene Mutations May Boost Breast Cancer Risk Read more »
September 17, 2016 – Breast cancer is the most common cancer in women worldwide, with nearly 1.7 million new cases diagnosed in 2012. In Europe, there were an estimated 464,000 new cases of breast cancer in 2012 and an estimated 131,000 …
Palbociclib (Ibrance): New treatment for advanced or metastatic breast cancer in the EU Read more »
Sacco K, Grech G EPMA J 2015;6(1):15 PMID: 26203310 Abstract Breast cancer is a heterogeneous disease that necessitates proper patient classification to direct surgery, pharmacotherapy, and radiotherapy. Despite patients within the same subgroup receiving similar pharmacotherapy, substantial variation in clinical …
Actionable pharmacogenetic markers for prediction and prognosis in breast cancer Read more »